{
    "clinical_study": {
        "@rank": "20270", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients\n      who have metastatic stomach cancer."
        }, 
        "brief_title": "DX-8951f in Treating Patients With Metastatic Stomach Cancer", 
        "completion_date": {
            "#text": "September 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Esophageal Cancer", 
            "Gastric Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Esophageal Neoplasms", 
                "Stomach Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the objective response rate of patients with previously untreated metastatic\n           gastric cancer treated with exatecan mesylate (DX-8951f).\n\n        -  Determine the time to tumor progression in this patient population when treated with\n           this drug.\n\n        -  Determine the survival at 6 and 12 months in this patient population when treated with\n           this drug.\n\n        -  Determine the quantitative and qualitative toxic effects of this drug in this patient\n           population.\n\n        -  Determine the pharmacokinetics of this drug in the plasma of these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive exatecan mesylate (DX-8951f) IV over 30 minutes on days 1-5. Treatment\n      repeats every 21 days for at least 2 courses in the absence of disease progression or\n      unacceptable toxicity.\n\n      Patients are followed every 3 months.\n\n      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 12\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed gastric or gastroesophageal adenocarcinoma\n\n               -  Lymph node involvement and/or distant metastasis\n\n          -  No squamous cell carcinoma, small cell carcinoma, lymphoma, or leiomyosarcoma of the\n             stomach\n\n          -  Measurable disease with indicator lesions outside the field of prior radiotherapy\n\n               -  At least 20 mm by conventional scan OR\n\n               -  At least 10 mm by spiral CT scan\n\n               -  Nonmeasurable lesions include the following:\n\n                    -  Primary tumor\n\n                    -  Bone lesions\n\n                    -  Leptomeningeal disease\n\n                    -  Ascites\n\n                    -  Pleural/pericardial effusion\n\n                    -  Inflammatory breast disease\n\n                    -  Lymphangitis cutis/pulmonitis\n\n                    -  Cystic lesions\n\n                    -  Abdominal masses not confirmed and followed by imaging techniques\n\n          -  No prior treatment for locally advanced or metastatic disease\n\n               -  Prior adjuvant treatment allowed if disease recurrence noted at least 6 months\n                  after completion of adjuvant treatment\n\n          -  No known brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Hemoglobin at least 9.0 g/dL\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2.0 mg/dL\n\n          -  AST or ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if\n             liver metastases present)\n\n          -  Albumin at least 2.8 g/dL\n\n          -  PT or INR no greater than 1.5 times ULN (coumadin independent)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n        Cardiovascular:\n\n          -  No active congestive heart failure\n\n          -  No uncontrolled angina\n\n          -  No myocardial infarction within the past 6 months\n\n        Other:\n\n          -  No concurrent serious infection\n\n          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or\n             carcinoma in situ of the cervix\n\n          -  No overt psychosis, mental disability, or incompetence that would preclude informed\n             consent\n\n          -  No other life-threatening illness\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  See Disease Characteristics\n\n        Biologic therapy:\n\n          -  No concurrent anti-cancer biologic therapy\n\n          -  No concurrent prophylactic colony stimulating factors during first course of therapy\n\n        Chemotherapy:\n\n          -  Recovered from prior adjuvant chemotherapy\n\n          -  No other concurrent anti-cancer chemotherapy\n\n          -  No other concurrent anti-cancer cytotoxic therapy\n\n        Endocrine therapy:\n\n          -  Concurrent megestrol for appetite stimulation allowed\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  No prior wide-field radiotherapy to more than 25% of bone marrow\n\n          -  No concurrent anti-cancer radiotherapy\n\n        Surgery:\n\n          -  At least 4 weeks since prior major surgery and recovered\n\n          -  No concurrent anti-cancer surgery\n\n        Other:\n\n          -  No other investigational drugs (including analgesics or antiemetics) for at least 4\n             weeks prior to, during, and for 4 weeks after study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00017212", 
            "org_study_id": "CDR0000068663", 
            "secondary_id": [
                "DAIICHI-8951A-PRT028", 
                "SACI-IDD-00-27", 
                "UTHSC-0015011134"
            ]
        }, 
        "intervention": {
            "intervention_name": "exatecan mesylate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Exatecan", 
                "Camptothecin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage III gastric cancer", 
            "stage IV gastric cancer", 
            "recurrent gastric cancer", 
            "stage III esophageal cancer", 
            "stage IV esophageal cancer", 
            "recurrent esophageal cancer", 
            "adenocarcinoma of the stomach", 
            "adenocarcinoma of the esophagus"
        ], 
        "lastchanged_date": "May 15, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DAIICHI-8951A-PRT028"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90813"
                    }, 
                    "name": "Pacific Shores Medical Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Rocky Mountain Cancer Centers"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75235-9154"
                    }, 
                    "name": "Simmons Cancer Center - Dallas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas - MD Anderson Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229-3264"
                    }, 
                    "name": "Cancer Therapy and Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Cancer Care Ontario-Hamilton Regional Cancer Centre"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "official_title": "A Phase II Study Of Intravenous Exatecan Mesylate (DX-891F) Administered Daily For Five Days Every Three Weeks To Patients With Previously Untreated Metastatic Gastric Cancer", 
        "overall_official": {
            "affiliation": "Daiichi Sankyo Inc.", 
            "last_name": "Robert L. DeJager, MD, FACP", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00017212"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "16133799", 
            "citation": "Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs. 2005 Oct;23(5):479-84."
        }, 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Cancer Care Ontario-Hamilton Regional Cancer Centre": "43.244 -79.889", 
        "Cancer Therapy and Research Center": "29.424 -98.494", 
        "Pacific Shores Medical Group": "33.804 -118.158", 
        "Rocky Mountain Cancer Centers": "39.739 -104.985", 
        "Simmons Cancer Center - Dallas": "32.803 -96.77", 
        "University of Texas - MD Anderson Cancer Center": "29.76 -95.369"
    }
}